Leukemia: Blood Cancers Explained

Leukemia is a malignancy of the blood and bone marrow characterized by the uncontrolled proliferation of abnormal white blood cells. It represents one of the most clinically complex cancer categories, spanning four major subtypes with distinct biological behaviors, treatment protocols, and patient demographics. Understanding leukemia's classification, mechanism, and clinical decision points is foundational to navigating the broader landscape of oncology care.

Definition and scope

Leukemia is classified by the National Cancer Institute (NCI) as a cancer that starts in blood-forming tissue, most commonly the bone marrow, and causes large numbers of abnormal blood cells to be produced and enter the bloodstream (NCI Surveillance, Epidemiology, and End Results Program). The disease is not a single entity but a family of related malignancies divided along two primary axes: the speed of progression (acute vs. chronic) and the cell lineage affected (lymphoid vs. myeloid).

The four major subtypes recognized by the World Health Organization (WHO) Classification of Haematopoietic and Lymphoid Tumours are:

  1. Acute Lymphoblastic Leukemia (ALL) — rapid onset; primarily affects children and accounts for approximately 75% of childhood leukemia diagnoses (NCI SEER).
  2. Acute Myeloid Leukemia (AML) — rapid onset; the most common acute leukemia in adults, with a median diagnosis age in the mid-60s.
  3. Chronic Lymphocytic Leukemia (CLL) — slow progression; the most prevalent leukemia type in adults in Western countries.
  4. Chronic Myeloid Leukemia (CML) — slow to moderate progression; strongly associated with the BCR-ABL1 gene fusion on the Philadelphia chromosome, present in more than 90% of CML cases (American Cancer Society).

The NCI estimated approximately 59,610 new leukemia diagnoses in the United States for 2023, accounting for roughly 3.2% of all new cancer cases (NCI SEER Cancer Statistics).

The regulatory and clinical oversight framework for leukemia diagnosis and treatment falls under the U.S. Food and Drug Administration (FDA) for drug approvals, the Centers for Medicare & Medicaid Services (CMS) for coverage determinations, and the National Comprehensive Cancer Network (NCCN) for evidence-based clinical practice guidelines. The regulatory context for oncology shapes which therapies reach patients and under what conditions.

How it works

Leukemia originates when a single hematopoietic (blood-forming) stem cell or progenitor cell acquires genetic mutations that disrupt the normal balance between cell proliferation and programmed cell death (apoptosis). These mutations cause the cell to replicate without restraint, producing large populations of immature or functionally defective blood cells called blasts.

In acute leukemias, blasts accumulate rapidly in the bone marrow, crowding out normal red blood cells, platelets, and functional white blood cells. This crowding produces the hallmark clinical triad of anemia (low red cells), thrombocytopenia (low platelets causing bleeding risk), and immunosuppression (insufficient functional white cells). Symptoms can appear within days to weeks of disease onset.

In chronic leukemias, the malignant cells are more mature and retain partial function. Progression is measured in months to years. CML, for example, follows a three-phase trajectory recognized in WHO guidelines: chronic phase, accelerated phase, and blast crisis. The blast crisis phase clinically resembles acute leukemia and carries significantly worse prognosis.

The BCR-ABL1 fusion gene in CML produces a constitutively active tyrosine kinase enzyme. This specific molecular driver made CML the prototype disease for targeted therapy, with imatinib (Gleevec) becoming the first tyrosine kinase inhibitor approved by the FDA for this indication in 2001.

Diagnosis requires bone marrow biopsy and aspiration, flow cytometry to characterize cell surface markers, cytogenetic analysis (karyotyping), and increasingly, molecular profiling to identify actionable mutations — processes detailed in molecular profiling and biomarkers.

Common scenarios

Pediatric ALL is the most statistically favorable leukemia scenario. The 5-year relative survival rate for children under 15 diagnosed with ALL exceeds 90% in the United States, according to NCI SEER data (NCI SEER). Standard treatment follows risk-stratified protocols developed by the Children's Oncology Group (COG), typically spanning 2 to 3 years of chemotherapy.

Adult AML presents a contrasting picture. The 5-year relative survival rate for AML across all ages is approximately 31.7% (NCI SEER), though this figure varies dramatically by cytogenetic subtype and patient fitness. Patients with favorable-risk mutations (e.g., core-binding factor AML) achieve remission more reliably than those with complex karyotypes.

CLL commonly presents as an incidental finding on a routine complete blood count (CBC), with absolute lymphocyte counts elevated above 5,000 cells per microliter. A subset of CLL patients require no immediate treatment — a strategy called "watch and wait" — while others progress to requiring chemotherapy, targeted agents such as BTK inhibitors, or bone marrow and stem cell transplantation.

CML in chronic phase is now managed predominantly with oral tyrosine kinase inhibitors, transforming what was once a rapidly fatal disease into a chronic manageable condition for the majority of patients who achieve major molecular response.

Decision boundaries

Clinicians use established criteria to navigate treatment decisions in leukemia. Key decision thresholds include:

  1. Blast percentage: A bone marrow blast count of 20% or greater defines acute leukemia under WHO criteria, distinguishing it from myelodysplastic syndromes (MDS) and necessitating immediate treatment planning.
  2. Cytogenetic risk stratification: AML is classified into favorable, intermediate, and adverse risk groups based on chromosomal and molecular findings. The European LeukemiaNet (ELN) 2022 guidelines provide the reference classification system used internationally.
  3. Measurable residual disease (MRD): Post-treatment MRD status — detectable disease below morphologic visibility — is increasingly used as a treatment response endpoint and guides decisions about transplant candidacy in both ALL and AML.
  4. Patient fitness scoring: The Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) quantifies transplant-related mortality risk and determines eligibility for allogeneic bone marrow or stem cell transplant.
  5. Philadelphia chromosome status in ALL: Ph+ ALL requires the addition of tyrosine kinase inhibitors to chemotherapy backbones and carries different prognostic implications than Ph− ALL.
  6. Enrollment in clinical trials: NCCN guidelines recommend clinical trial participation as a preferred option at multiple disease stages, particularly for relapsed or refractory disease.

The distinction between leukemia and lymphoma — both hematologic malignancies — rests primarily on anatomical origin and disease behavior. Leukemia arises in the bone marrow and circulates in the blood; lymphoma primarily involves lymph nodes and lymphatic tissue, though both can overlap in advanced presentations.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)